Share Name Share Symbol Market Type Share ISIN Share Description
Eden LSE:EDEN London Ordinary Share GB0001646941 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.15p +1.49% 10.20p 137,812 08:35:19
Bid Price Offer Price High Price Low Price Open Price
9.70p 10.70p 10.20p 10.05p 10.05p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1.88 -0.76 -0.33 21.1

Eden (EDEN) Latest News

More Eden News
Eden Takeover Rumours

Eden (EDEN) Share Charts

1 Year Eden Chart

1 Year Eden Chart

1 Month Eden Chart

1 Month Eden Chart

Intraday Eden Chart

Intraday Eden Chart

Eden (EDEN) Discussions and Chat

Eden Forums and Chat

Date Time Title Posts
25/9/201822:44Eden Research4,565
25/9/201816:48Eden Research; novel encapsulation and delivery technologies104
07/3/201713:47Eden Research- The Natural Solution172
27/2/201611:20Eden Research- The Natural Solution3
18/5/201202:24Eden Research6

Add a New Thread

Eden (EDEN) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2018-09-25 16:18:1910.35101,00010,453.50O
2018-09-25 15:04:1610.243,000307.06O
2018-09-25 15:01:3110.1910,0001,019.40O
2018-09-25 12:48:489.7269567.55O
2018-09-25 11:35:099.7267365.42O
View all Eden trades in real-time

Eden (EDEN) Top Chat Posts

DateSubject
25/9/2018
09:20
Eden Daily Update: Eden is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker EDEN. The last closing price for Eden was 10.05p.
Eden has a 4 week average price of 10p and a 12 week average price of 9.75p.
The 1 year high share price is 16.05p while the 1 year low share price is currently 7.30p.
There are currently 207,189,337 shares in issue and the average daily traded volume is 36,169 shares. The market capitalisation of Eden is £21,133,312.37.
04/9/2018
15:50
investingisatrickygame: Who sells 100,000 shares today at 10.58p when Eden says The interims will be published in the coming weeks (September) TT to deliver income in 2018 Bayer will do the same in 2018 Multiple Sipcam updates on co-encapsulation, distribution rights & more Eastman update Appointment of a US distributor for Mevalone (mentioned 21/3/2018, Proactive Video) PLUS anything else that has not yet been made public knowledge. Unless under severe financial stress, surely Eden can do more to protect investors from themselves. Surely there should be a lead into all of the above, updates, communication. The Eden share price needs a band aid until such time as it is healthy enough to look after itself!!!!!!
03/8/2018
16:57
investingisatrickygame: Bjik From your email "Share price movement is not one of the targets of bonuses due to the short-term nature of annual bonus payments. Rather, the executive team is incentivised on a longer term basis via a long term incentive programme where our interests are tied directly to those of shareholders and where our actions should support longer term share price appreciation." That is a very interesting statement. Most people investing would not consider, in my opinion, 12 months short-term and in the long-term, everyone is not going to sit around hoping for an Apple inc return of 50,000-1. Share price appreciation should be progressive and that includes the short-term of 12 months. Had those invested known that there is no real incentive to invest for the next 12 months (whatever historical 12 month period that was), then I imagine they would have gone elsewhere and not left dead money in Eden, preferring to review Eden in a years time. The long-term incentive plan aligns the executives with the executives! It may well align the executives with some shareholders, but most definitely not all or I doubt, the majority. It is not unreasonable for all shareholders to expect a return on their investment within the year, albeit, not as large as longer term investors who hopefully reap the rewards of greater commercial success. To acknowledge the fact that there will be little or no return within a year merely encourages investors to look elsewhere on AIM or other markets and seek out companies who both want their investors hard earned monies and offer a good shot at a decent return. Eden for me, doesn't get the private investor, their motivations, their needs, their wants, the reasons why they invested. Eden doesn't work in tandem with those shareholders to deliver the same. Executives motivations for their shareholding when they work in the Company, are handsomely rewarded and can wait 5 years for a return. These are misaligned with the average AIM investor. Eden should ask themselves "there are 1,000 companies on AIM. What makes an investment in our company more compelling than putting your money elsewhere". When they answer that question fully, they will understand why theirs and our share price is stuck @ circa 12pence and going nowhere. Investor pounds need to be fought for, earned and respected in order to retain and build your investment community and share price. If you don't, your share price is always at the negative mercy of 'dead money'!
14/6/2018
09:38
investingisatrickygame: I am stupefied as to why Eden would release an RNS such as they have this morning. On the one hand, the Company writes about 'significant commercial progress', 'inflexion point', being 'very far advanced' and 'that the Company has 'shifted gears' and yet it delivers, in isolation, an RNS under the heading 'Regulatory Progress Update' that screams of jam tomorrow and therefore indicates to some that there is no reason to be invested in Eden now. Within this RPU there is nothing on Terpene Tech! I have no doubt other RNS's will follow pre the AGM as I commented recently, but If I was releasing this RNS it would be embedded in another or separately I would accompany its release with more info elsewhere, either another separate RNS or another form of communique. Who is advising Eden on the 'how to' of these announcements? It is bizarre to me. Eden needs to gear up in the way it communicates and still needs to tell its story properly. They just do not do it. Some who are absolutely converted will sit and wait forever hoping that Eden will become an extremely profitable company and player in the tech and biopesticide market, but for the majority invested here, Eden will not take a lot of their time and their belief system and price expectation will be considerably lower. In my opinion, Eden needs to deliver and communicate properly that they have delivered the kind of success that they refer to. What are our Mevalone product sales to-date (2018) When will the next Mevalone orders occur? What is the value of the Company and if we do not know it, then let's get a professional valuation done. What is going on with Terpene Tech that has 16 days left to go commercial according to Eden? What is going on with Bayer which has a similar time period as inferred by Eden (sales will occur in H2 2018) These 5 basics alone could multiply the share price, yet we don't know any of them. Eden does not do hype and good for them! Eden is not understated either Eden just doesn't communicate properly, period! This doesn't allow investors to make proper investment decision in the Eden share price. Consequently, some poor individuals might be selling shares when Eden could, in theory, be much higher very soon. Much more clarity and far better execution is needed if Eden is going to see their share price rise and for the share price rise to be...…..sustainable!!!! Forgive me, I couldn't help myself :)
17/5/2018
12:02
investingisatrickygame: paulpaolo, Eden is extremely interesting to those that follow it with great interest, but I doubt their whole share register does and some will only be in it for a quick buck. There is possibly a small number of people that think Eden is the wholly grail and as such are very knowledgeable on the Company and is willing them to do well. Given that Eden is very interesting and maybe not your run of the mill investment prospect they should convey how interesting Eden is and their prospects. They totally fail to do that. There should be far more interest in Eden right now and the shares should be far more lively to the positive. How can you be a commercial company which Eden are, revenues coming in and with game changing tech for the agro-chemical industry and sit at a lowly £26 million market cap? If people read/research what Eden do and like the story the first thing they will then do is look at price and value and that will immediately raise questions as to why it is so low. They will then look at management and communications and then they might look at advisors and their role. It is very disappointing to me that Powerscourt has not had more impact on Eden given all the braggs on the Powerscourt website. They may have secured some analysts meetings, but what else? They also appear to have had little influence in 'change' with Eden. Eden's prospect base still is private investors. Some may see me/this post as moaning or being critical of the Company, but the reality is that the trend with Eden is consistent and nothing is changing for the investor or prospective investor. Investors cannot continually have faith when a Company doesn't deliver and the only delivery the investor is interested in or even invested in, is the share price. I have been invested in companies before where management keep PI's at arms length and choose to ingratiate themselves with their professional investors. The story is great, but the delivery is poor. My personal experiences of this has been that the various BoD's are uncertain around social/business media and tend to stray away from the same. The PR companies continue to do what they do historically for their monthly subscription delivering zero results. They are a very expensive, non- productive, nice to have. I was also hoping that we would have heard more from our newly appointed Chairman and ex Bayer senior employee. To-date, he has been silent with the exception of his commentary in the prelims. I appreciate that (hopefully) he is proving invaluable internally and supplier side. That said, he has a weighty CV and Eden should be using this to their advantage and to the advantage of the share price which is likely so far behind where is should be relative to commercial productivity and progression. Why has the Chairman not stepped forward in a delivery to investors (private and all)to elaborate on his appointment, decision making for the same and the immediate and mid-term prospects as he see's them. Also some discussion and opinion around value. Surely this would invigorate the share price. Equally, with all this EU chemical pesticide fuss, why is Powerscourt not promoting him to the press given his stature. To be fair, they may have done so with zero success, but I imagine that unlikely. Assuming they haven't, why did Eden not call all of the recent journalists who ran the same story and invite them to H/O or Powerscourt's office to introduce Eden to them and the tremendous headway Eden is making on a global scale. There is so much that Eden and Powerscourt could do to the positive, without egg on their face and without immense time. Allowing for the regulatory process and the time that takes, Eden must have time in their calendar to consider and employ the same. Eden is VERY interesting, it is just a shame that more people are not aware of it.
22/4/2018
15:53
investingisatrickygame: Super, "The Tortoise and the Hare. I often wonder why Eden has not been swallowed up.. maybe were in a perfect storm where the big boys are just too busy chasing monopolistic hegemony." I used to wonder about that, but although they had innovation, they hadn't proved it commercially. 1) Proved it in commercial sales 2) Proved it in the commercial field, adopted by farmers and re-ordered for the following year (will happen in 2018) 3) Had the commercial acceptance of a strategic, world reaching partner (Sipcam) that will undoubtedly be acknowledged by other industry players The following is all personal opinion, is repetitive, but to me it is very valid to Eden absolutely being a potential takeover target now A)The Chairman said in his prelim report we are at an inflexion point. I take that to mean that commercially we are about to 'lift off' AND that in turn will have the industry pay closer attention to Eden B)The Sipcam 'very far advanced' situation in regards to Sustaine will effectively launch Sustaine into the R and D and commercial teams of Agro-Chemical players. How long for them to develop their own, can they protect existing patents under threat now, should they buy Eden for that technology or do a commercial deal for that technology C)Should Bayer come on board now, commercially for those 4 animal health care products, let alone Bayer Crop sciences having 9 products coming off patent with a value of circa $1.6 billion https://bit.ly/2qQ0qfS Eden could, as a result of B) form a company with Sipcam and put Sustaine in it and licence the same to both Sipcam and Eden in perpetuity. This would have the benefit of separating the tech and allowing it to stand-alone and perform alone. Eden quotes, to my mind, irrelevant numbers in their presentations in regards to market sizes https://bit.ly/2kEdUIj slide 8. Eden will never penetrate that market with product, however, it could change the industries delivery of product with its tech and thus penetrate the market in a very substantial way. Think of Ford Motor Company with windscreen wipers and now every car has them. So Eden could have a decision to make; to be a product company or a tech company. Eden could be a tech company and Sipcam could be the downstream deliverer of Eden/Sipcam product, globally, for any market. Back to the point of why Eden has not been taken over or an offer made. I believe the announcement due from Eden re the development with Sipcam and the tech could be the catalyst to that and that the subsequent deal with Bayer will only further enhance Eden's credentials. There is massive potential value in Eden going forward which I doubt they will realise. So a three-year forward evaluation of revenue and P and L from 1) Mevalone 2) Cedroz 3) Bayer 4) Sipcam arrangement 5) Co-encapsulation and stand-alone encapsulation will exploit Eden and make them a target to potentially bid for. With a current share price of 11.5 pence, an offer of say 50 pence will look very attractive to most investors. I imagine Eden would then want to tell us why that is unacceptable, but I doubt they have the share register support to absolutely reject such a bid, should it come along. It would be helpful in light of where Eden now is, commercially, if Shore Capital or another would do a full evaluation of the above to ascertain a fair price/value for Eden to be trading at. This would stir up the market, Eden could talk about and endorse the same to their various markets and the share price would likely rise. At this stage, they would then have more supporters on their side, should a cheap bid come along which they wish to defend. We will see super, but I think both you and I and no doubt others, feel that a bid is definitely a potential outcome and with the pipeline announcements above (+ Terpene Tech), then that could even come this calendar year.
20/3/2018
09:36
investingisatrickygame: Super "Shifted gears" and the share price is going backwards "The engine of future growth" "We are accelerating our collaborative work to fully demonstrate the value of our encapsulation technology" Explain these three in full and you get share price appreciation. The Company statements made today are fine. To be fair they are very positive. But, I will continue to argue about who is listening. 1) Existing shareholders that are enthusiastic about Eden....Yes 2) Existing shareholders that have lost patience with the Company and enthusiasm for the share price.....no What about all those potential investors who do not know about Eden and need it explained to them to be encouraged to make an investment......no These statements come in the context of regulatory financial PR via RNS. The broader non-invested market do not see these statements. They are not looking for them. Powerscourt is unlikely to get press coverage on this, but they will engage in the same in 6 months. Shore Capital cannot bring investment in on the back of this with Eden's market cap at £16 million + So, where do you go to get investment in Eden's share price? EXECUTION ONLY Retail Investors, Retail Investors, Retail Investors!!!!!! Use the story to mobilise their funds to get you to the next level When at the next level, try and command more interest from Private Client Brokers, Wealth Managers and HNW individuals Then, perhaps, the Brokers, Shore Capital will have a shot at bringing in investment to the Eden share price AND THEN perhaps, will a mobilised share price, someone may grant Powerscourt a story in the press, a national newspaper. Again, this is not investor communications, but a good news story that may gain some traction. Moving the share price up will get people's attention. The "Outlook" and other statements are fine for those currently invested. But they have likely invested enough and will not make further commitments (risk) without some commitment to the share price from the Company. If the Company makes a solid commitment to do better in this respect, then others will likely follow.
21/2/2018
09:30
investingisatrickygame: PaulPaolo, The Company will now be in a closed period for sure meaning Director buys are not possible. However, as Northwick has pointed out, this is not always so and therefore Directors could have purchased shares in the past. This of course requires 1) personal funds and 2) belief that they will make money. They earn good money, but I never assume, to be fair to any Director, that they have available funds. They could still be in a closed period post results IF Terpene Tech, Bayer or any other news is still due, not yet released and thought to be significant enough to move the share price. I have to laugh a bit at this last statement because although it is fact, nothing ever moves the Eden share price!!!!! I wonder why:) ? A downside to Director purchases in the sometimes misplaced timing and generosity of the Remuneration Committee who award options to Directors of Plc Companies, particularly small AIM listed companies where roles often overlap. The option awards, nearly always adjusted by new options if the old options are not or do not look like being 'in the money' are a deterrent from Directors purchasing shares as they are nearly always over generous and the milestones of achievement very rarely are in line with share price performance. So the award structure and catalyst to exercise are wrong. All Directors of listed companies should be exposed to share price and capital risk. This should be mandatory, once again, so they are truly aligned with investors. Until that is so, there will never be a level playing field.
16/2/2018
13:22
investingisatrickygame: Paulpaolo, It is a concern isn't it, little or no trading in Eden and the question of why. To be honest, I think the answer is very simple and can be split as follows:- 1) Long standing shareholders in at much higher prices probably feel they have little more to lose so their shares sit redundant. Add this to the 'institutional' holdings as per the published share register information on Eden's website and this likely accounts for an enormous amount of the 207 million shares in issue 2) Assuming the above to be correct, this means that few new investors have come into Eden in any meaningful way 3) A primary reason for this in my opinion, is that Eden chooses not to properly communicate its story and therefore the investment proposition. As a result, few are motivated to buy in and a lot more won't even know about Eden. So, Eden's investment reach is very poor 4) Those that do know about Eden, but have not invested, possibly see it as a slow burn and again, see no impetus or corporate direction to instil an alternative belief The net and understandable result is no momentum in Eden's share price, a likely vastly undervalued Eden share price and a tremendous lack of investment eyes monitoring Eden. RNS informs us what has happened Investor Communications communicates understanding to us and reasons why we should invest and is therefore a driver for the share price Eden, sadly, only participates (because it is regulatory) in the RNS channel and defacto abandons the share price and those invested who sit on zero gains. It's morally wrong in my book. You participated in an IPO, sold your initial story, raised your money, went back to the market a few times for more money and yet you build no relationship with your investors to feel good about the prospects of making a return. So people could sell out as you say, but I expect people to stay invested and on any good news that propels the share price, I anticipate a tsunami of selling. This of course, should it happen, would require Eden to consider this eventuality and have a plan for 'others' to mop up those shares and thus have a new share register with possibly a higher floor under the share price. By the way, can someone please elaborate on one thing that Powerscourt has brought to the table or executed since their appointment 5 months ago. Massively disappointing, but all so predictable and consistent with PR firms appointed. What a waste of money!
11/1/2018
10:24
investingisatrickygame: So we have some commentary to the positive on here. When I read that trading statement I hear Eden saying at the beginning post numbers "This was a good performance since the 2017 growing season was challenging for fungicidal products in many southern European countries due to hard frosts in April followed by high heat and drought in the summer. These well-documented conditions resulted in the smallest harvests in 60 years in key markets such as France and Italy." AND IN THEIR LAST LINE ""Despite challenging growing conditions in key territories and a shortened marketing campaign in France, we are pleased with the progress made in 2017 and we look forward to providing a further update when we report our full year results for the year ended 31 December 2017 in March." So they start on an excuse and finish on one too. Now we all know the story (presumably), but if you want to entice new money in from this RNS, where is the incentive to do so? There is no apparent need to jump in today and so there will be no northward mobilisation of the share price. EDEN do not know how to build a story or tell it. Where is their professional help, Powerscourt, in all of this? They have been on RNS's since the first of September 2017, employed since the first of October 2017 and we are now 3.5 months into their tenure, 25% in time of their annual contract. I don't think the market has heard anything from them. So what is the step-change that they have delivered since Eden removed Walbrook PR? I'm guessing Powerscourt is also more expensive per month than Walbrook. History shows that these PR companies are a waste of shareholder funds and operational funds. If Eden is a ground-breaking industrial biotech then why is Powerscourt unable to deliver a narrative? To me, this is quite remarkable. I can see that Eden has good products and potential. Biotech will also trade on excellent P/E's. Eden is looking at solving global agricultural issues. But where is the story,the building story? Where is the commitment to engage and deliver value into the share price? Where is the recognition of shareholder funds invested and the need to provide a return on invested capital? Where is the alignment between board and shareholder? To me there isn't one and so again, Eden is to blame for the share price and appears to learn nothing from the past. The RNS channel in isolation delivers no value to the Eden share price. The engagement of a hot shot communications firm has done nothing to assist the share price. Shore Capital are impotent so who cares what their broker note says. Overall, Eden is becoming very underwhelming. If the products and patents are that good, then come the commercial announcements of Bayer and TT, I wouldn't be surprised to perhaps see someone sniffing around with a very cheap offer that Eden would struggle to defend. And even if they did defend such a situation, I doubt shareholders would listen because there is no strong relationship between the two that would encourage shareholders to listen.
17/7/2017
12:37
investingisatrickygame: Eden has clearly gone commercial and in what we hope is a successful and profitable way. With Sipcam SpA being a major distributor in this sector and product creator, their chosen alliance and investment in Eden with a clause that restricts the selling of their shares for 3 years is a welcome one. Equally, so too will be their board appointment. This all adds commercial weight and gravitas to Eden's development and is very welcome. Eden has clearly developed a niche in both its slow release system and with its management of volatile terpenes, natures own defence mechanism. In fact, the very nature of controlling volatility to enable a product to work defensively against disease is a very creative one and one that evidently the majors hadn't thought to do or were unable to do. Patent protection will now secure Eden's ability to deliver revenue through commercial agreements that should deliver substantial profits. This is one side of Eden Research Plc's business, one collective product area and although some feel it has been slow, it is now here, it is real and management definitely deserve credit for delivering the same. Successful sales of 3AEY now rest, predominately with Sipcam SpA and Sumi-Agro France. In effect this should be a collective effort, one would assume, given their relationship to Sumitomo, whom I assume, are also keeping a keen eye on developments. I imagine they will be looking at Sipcam SpA to monitor how the collaborative elements of the arrangement unfold in regards to new product development, expansive use of Eden's Sustaine technology and extended patent life of existing SpA pesticides. I wouldn't mind betting that internally, they also have a value attached to the same which easily outweighs their £2 million stock investment in Eden. They will also see additional value back to them through an increase in Eden's market capitalisation. What I now hope to see is Eden and Sipcam manage their other product in their portfolio, namely their share price. Given its volatile nature, one could easily draw a line to the management of terpenes to create an easy understanding for the need to reduce negative volatility in their share price. The share price may arguably be stable now, but it is stable at a very low price, to the negative if you will. Some simple time and strategies to complement their operational product areas will be very welcome, especially now that they have some breathing space to do the same with 3AEY over the line and funds in the bank and on the way. Successfully delivering 3AEY gives Eden breathing space to now move on to other product developments, other commercial arrangements and more (notwithstanding Eden wants 3AEY registered in other countries around the globe). If Eden and Sipcam could successfully manage Eden's share price to fair value today, it would be for the benefit of both parties, reward institutional and retail shareholders who will no doubt feel more confident in spreading the word, whilst not necessarily selling up given the greater confidence and visibility they would then have. If they can manage volatile terpenes, I'm confident with all that they have to offer that they can manage a volatile share price. It is after all, one of the fundamental reasons that they, along with others, became a listed Plc.
Eden share price data is direct from the London Stock Exchange
add chat code
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V: D:20180926 03:26:05